All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humansInterventional
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Seagen Inc.
Enrolment target
82
Start
26 Jul 2022
gastroesophageal junction [GEJ] carcinomaNon-small cell lung cancer (NSCLC)Gastric cancerCervical cancerOvarian cancerEndometrial cancerMalignant ovarian GCT with the exception of pure teratomasMalignant testicular germ cell tumor (GCT) with the exception of pure teratomasGastroesophageal junction carcinomaMalignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS)
What is this study about?
Type, incidence, severity, seriousness, and relatedness of adverse events (AEs) and type, incidence, and severity of laboratory abnormalities, Incidence of dose-limiting toxicities (DLTs), Incidence of DLTs and cumulative safety by dose level
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (4)
- —Spain
- —Sweden
- —Netherlands
- —Denmark
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.